Improving Completion Rates for Therapy of Latent Tuberculosis

In a post hoc analysis, missing an early clinic visit significantly increased the odds of not completing therapy, regardless of regimen.

An important component in the strategy to eliminate tuberculosis is the treatment of latent infection (LTBI). However, completing such therapy is a challenge. Regimens with shorter durations and fewer adverse effects are more likely to be successful. However, other factors associated with noncompletion of treatment (NCT) for LTBI remain incompletely defined. To provide insight into these other factors, researchers performed a post hoc analysis of data from 6232 North American participants in the PREVENT TB trial (NEJM JW Infect Dis Jan 2012 and N Engl J Med 2011; 365:2155), which compared daily self-administered isoniazid for 9 months (9H-SAT) with a 3-month course of directly observed, once-weekly rifapentin and isoniazid (3HP-DOT).

NCT was…

Reviewing Author

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Neil M. Ampel, MD

Disclosures

Editorial BoardsUpToDate

Leadership Positions in Professional SocietiesCoccidioidomycosis Study Group (Past President, Secretary, Treasurer)

Improving Completion Rates for Therapy of Latent Tuberculosis

Topics

Reviewing Author